Fig. 3

NETosis-derived products are augmented in r-axSpA patients and are biomarkers associated to r-axSpA and disease activity. a Circulating levels of NETosis-derived products. Values are represented as mean ± SEM (HDs, n = 32; r-axSpA patients, n = 30). The data were analyzed using an Independent Samples t test. *vs. HDs (P < 0.05). b ROC curve analyses of the NETosis-derived products and a combination of these as a panel were performed to assess their potential as biomarkers associated to r-axSpA. A cut-off value with higher specificity and sensitivity was tested. c Spearman’s rank correlations between NETosis-derived products and clinical inflammatory parameters. d Circulating cell-free NETosis-derived products in active (n = 18) and non-active r-axSpA patients (n = 12). Data are shown as mean ± SEM. The data were analyzed using an Independent Samples t test. *vs. HDs (P < 0.05). e A ROC curve analysis of the circulating cell-free nucleosomes was performed to assess its potential as biomarker for disease activity in r-axSpA. A cut-off value with higher specificity and sensitivity was tested. AU, arbitrary units; AUC, Area Under the Curve; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HDs, healthy donors; IL, interleukin; r-axSpA, radiographic axial spondyloarthritis; ROC, receiver operating characteristics; TNF, tumor necrosis factor